Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) traded up 50% during trading on Thursday . The company traded as high as C$0.02 and last traded at C$0.02. 205,000 shares were traded during mid-day trading, an increase of 5% from the average session volume of 195,263 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Up 50.0 %
The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The company has a market cap of C$1.99 million, a P/E ratio of -1.50 and a beta of 0.05. The stock has a 50-day moving average of C$0.02 and a 200 day moving average of C$0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 9/16 – 9/20
- Why Invest in 5G? How to Invest in 5G Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
